tbuckley/cabot-search huggingface dataset:
Efficacy, tolerance and immunohistological analysis (IHA) in the group of 52 patients in inflammatory stage IIIB breast cancer (IBC) treated with F-FEC regimen
Authors: M. Wagnerova, I. Andrasina, L. Sokol, K. Jutka, A. Berc, T. Packan, P. Matula
Journal: Journal of Clinical Oncology (2005)

840 Background: IBC is the most lethal form of locally advanced breast cancer (LABC). Primary systemic chemotherapy (PSCH) is commonly used as initial treatment of LABC however the best regimen is not known. The previously reported (J.C.O. Proc. ASCO 2001, Abstract 1813) results patient series regarding response and survival data are updated. Methods: This is the retrospective analysis of 52 patients (pts) with clinical, radiological signs and histological diagnosis of IBC between 01/92–01/00. The purpose of the study was to determine treatment results, toxicity and survival after PSCH with consequent radiotherapy (RT) and surgery and to evaluate RR in related of IHA. We analysed 52 pts with no evidence of metastatic disease who received 4 courses of F-FEC regimen with continuous administration of 5-Fu 750 mg/m2 days 2 to 5, Epirubicin 35 mg/m2 as bolus days 3 to 5 and CFA 400 mg/m2 days 1 to 5 in neoadjuvant setting. Higher dose intensity of PSCH was supported by administration of growth factors. PSCH was followed by hyper fractionated RT up to total dose 50 Gy (1,25 Gy bid) in 4 weeks. Modified radical mastectomy was performed afterwards. In case of presence of residual tumour at surgery the treatment was continued with altered adjuvant regimen and subsequently with TMX. Results: Mean age was 44 years, 47% premenopausal, 32% peri- and 21% postmenopausal pts. Tumour greater then 5 cm was found in 55%, axillary lymph nodes involvement in 89%; signs of localised inflammation in 58% and diffuse in 42%. ErR, PgR positivity was in 26% and negativity in 58%. 60% of pts expressed positive staining of p 53 and 20% of HER-2. Median follow up was 69 months. Results were evaluated according to WHO criteria. RR of 68% and pathological CR in 15% were observed. Five-year OS was 38% and DFS 32%. Locoregional failure was detected in 19% and metastatic disease in 43% of pts. Grade III-IV haematological toxicity was observed in one quarter of pts. Pts who showed positive staining of p53 and HER-2 responded to PSCH, but all pts who relapsed loco regionally or developed metastases was from this group either. Conclusions: PSCH with F-FEC is well tolerated with 68% response rate and 15% pCR rate. No significant financial relationships to disclose.
Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT.
Authors: Seitaro Terakura, Makoto Murata, Tetsuya Nishida, Nobuhiko Emi, Yoshiki Akatsuka, Stanley R. Riddell, Yasuo Morishima, Yoshihisa Kodera, Tomoki Naoe
Journal: Blood (2004)
Genetic Variants of Ataxia Telangiectasia Mutated (ATM) and Susceptibility for Childhood T-Lineage Acute Lymphoblastic Leukemia.
Authors: Marrit Meier, Monique L. Den Boer, Andrew G. Hall, Julie Irving, Monique Passier, Lynne Minto, Elisabeth R. Van Wering, Gritta E. Janka-Schaub, Rob Pieters
Journal: Blood (2004)
A Randomized Study of Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine in Patients with Hairy Cell Leukemia.
Authors: Reinhard Zenhausern, Nicolas Leupin, Shu-Fang Hsu Schmitz, Max Solenthaler, Andre Tichelli, Dominik Heim, Urs Hess, Leda Leoncini, Mario Bargetzi, Andreas Tobler
Journal: Blood (2007)
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth
Authors: Siyuan Xia, Ruiting Lin, Lingtao Jin, Liang Zhao, Hee-Bum Kang, Yaozhu Pan, Shuangping Liu, Guoqing Qian, Zhiyu Qian, Evmorfia Konstantakou, Baotong Zhang, Jin-Tang Dong, Young Rock Chung, Omar Abdel-Wahab, Taha Merghoub, Lu Zhou, Ragini R. Kudchadkar, David H. Lawson, Hanna J. Khoury, Fadlo R. Khuri, Lawrence H. Boise, Sagar Lonial, Benjamin H. Lee, Brian P. Pollack, Jack L. Arbiser, Jun Fan, Qun-Ying Lei, Jing Chen
Journal: Cell Metabolism (2017)
Augmenter of liver regeneration: A fundamental life protein
Authors: Michael A. Nalesnik, Chandrashekhar R. Gandhi, Thomas E. Starzl
Journal: Hepatology (2017)

1Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghPA 2Thomas E. Starzl Transplantation Institute, Department of SurgeryUniversity of Pittsburgh Medical CenterPittsburghPA 3Department of Pediatrics, Division of Gastroenterology, Hepatology & NutritionCincinnati Children's Hospital Medical CenterCincinnatiOH *ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:Thomas E. Starzl, M.D., Ph.D.Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center3459 Fifth AvenuePittsburgh, PA 15213E‐mail: [email protected]Tel: +1‐412‐383‐1346
Occupational health services.
Journal: BMJ (1972)

Medical surveillance via occupational medical examinations is the most widely tool used in prevention and control of job-related diseases. Its management by the occupational physician allows recognition of the occupational disease. By developing programs of preventive-promotional health and occupational examinations the Occupational Health Services make possible early recognition of labor health problems. Their goal is to prevent work-related diseases. Companies must establish and maintain labor health services integrated by specialized physicians in occupational medicine as head of a team that includes occupational nurses, industrial hygiene, and other technicians specialized in labor health-related fields.
Proton MR Spectroscopy and Diffusion MR Imaging Monitoring to Predict Tumor Response to Interstitial Photodynamic Therapy for Glioblastoma
Authors: Magali Toussaint, Sophie Pinel, Florent Auger, Nicolas Durieux, Magalie Thomassin, Eloise Thomas, Albert Moussaron, Dominique Meng, François Plénat, Marine Amouroux, Thierry Bastogne, Céline Frochot, Olivier Tillement, François Lux, Muriel Barberi-Heyob
Journal: Theranostics (2017)

Despite recent progress in conventional therapeutic approaches, the vast majority of glioblastoma recur locally, indicating that a more aggressive local therapy is required. Interstitial photodynamic therapy (iPDT) appears as a very promising and complementary approach to conventional therapies. However, an optimal fractionation scheme for iPDT remains the indispensable requirement. To achieve that major goal, we suggested following iPDT tumor response by a non-invasive imaging monitoring. Nude rats bearing intracranial glioblastoma U87MG xenografts were treated by iPDT, just after intravenous injection of AGuIX® nanoparticles, encapsulating PDT and imaging agents. Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) allowed us an original longitudinal follow-up of post-treatment effects to discriminate early predictive markers. We successfully used conventional MRI, T2 star (T2*), Diffusion Weighted Imaging (DWI) and MRS to extract relevant profiles on tissue cytoarchitectural alterations, local vascular disruption and metabolic information on brain tumor biology, achieving earlier assessment of tumor response. From one day post-iPDT, DWI and MRS allowed us to identify promising markers such as the Apparent Diffusion Coefficient (ADC) values, lipids, choline and myoInositol levels that led us to distinguish iPDT responders from non-responders. All these responses give us warning signs well before the tumor escapes and that the growth would be appreciated.
Src Family Kinase Inhibitor PP2 Has Different Effects On ATRA or Arsenic Trioxide-Induced Differentiation of Acute Promyelocytic Leukemia Cell Line
Authors: Kyoung Ha Kim, Hee-Jeong Cheong, Sook-Ja Kim, Young Woo Jeon, Jina Yoon, Han Jo Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan-Kyu Kim, Namsu Lee, Kyu Taeg Lee, Sung Kyu Park, Dae Sik Hong, Park Hee-Sook, Jong-Ho Won
Journal: Blood (2012)
Retargeting of Activated T Cells (ATC) with Gemtuzumab (anti-CD33) Ozogamicin x Anti-CD3 Bispecific Antibody (CD33-OBi) Enhances Cytotoxicity Directed at K562.
Authors: Abhinav Deol, Archana Thakur, Lawrence G. Lum
Journal: Blood (2009)
Rescue of Germinal Centre B Cells with Inactivated Immunoglobulin Genes by EBV In Vitro Suggests a Common Mechanism in the Pathogenesis of Post-Transplant Lymphoproliferative Disease and Hodgkin’s Disease.
Authors: Sridhar Chaganti, Noelia Begue-Pastor, Mark T. Drayson, Andy I. Bell, Alan B. Rickinson
Journal: Blood (2005)
Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention
Authors: Jarrod K. Betz, David F. Katz, Pamela N. Peterson, Ryan T. Borne, Sana M. Al-Khatib, Yongfei Wang, Carolina Malta Hansen, David D. McManus, Jehu S. Mathew, Frederick A. Masoudi
Journal: Journal of the American College of Cardiology (2017)
Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and <i>in vivo</i> Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets
Authors: Elmire Hartmans, Veronique Orian-Rousseau, Alexandra Matzke-Ogi, Arend Karrenbeld, Derk Jan A. de Groot, Steven de Jong, Gooitzen M. van Dam, Rudolf S.N. Fehrmann, Wouter B. Nagengast
Journal: Theranostics (2017)

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide.High adenoma miss rates, especially seen in high-risk patients, demand for better endoscopic detection.By fluorescently 'highlighting' specific molecular characteristics, endoscopic molecular imaging has great potential to fulfill this need.To implement this technique effectively, target proteins that distinguish adenomas from normal tissue must be identified.In this study we applied in silico Functional Genomic mRNA (FGmRNA) profiling, which is a recently developed method that results in an enhanced view on the downstream effects of genomic alterations occurring in adenomas on gene expression levels.FGmRNA profiles of sporadic adenomas were compared to normal colon tissue to identify overexpressed genes.We validated the protein expression of the top identified genes, AXIN2, CEMIP, CD44 and JUN, in sporadic adenoma patient samples via immunohistochemistry (IHC).CD44 was identified as the most attractive target protein for imaging purposes and we proved its relevance in high-risk patients by demonstrating CD44 protein overexpression in Lynch lesions.Subsequently, we show that the epithelial splice variant CD44V6 is highly overexpressed in our patient samples and we demonstrated the feasibility of visualizing adenomas in Apc Min/+ mice in vivo by using a fluorescently labeled CD44v6 targeting peptide.In conclusion, via in silico functional genomics and ex vivo protein validation, this study identified CD44 as an attractive molecular target for both sporadic and high-risk Lynch adenomas, and demonstrates the in vivo applicability of a small peptide drug directed against splice variant CD44v6 for adenoma imaging.
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis
Authors: Francesca Fornari, Daniela Pollutri, Clarissa Patrizi, Tiziana La Bella, Sara Marinelli, Andrea Casadei Gardini, Giorgia Marisi, Marco Baron Toaldo, Michele Baglioni, Veronica Salvatore, Elisa Callegari, Maurizio Baldassarre, Marzia Galassi, Catia Giovannini, Matteo Cescon, Matteo Ravaioli, Massimo Negrini, Luigi Bolondi, Laura Gramantieri
Journal: Clinical Cancer Research (2017)

Abstract Purpose: The aberrant expression of miR-221 is a hallmark of human cancers, including hepatocellular carcinoma (HCC), and its involvement in drug resistance, together with a proved in vivo efficacy of anti-miR-221 molecules, strengthen its role as an attractive target candidate in the oncologic field. The discovery of biomarkers predicting the response to treatments represents a clinical challenge in the personalized treatment era. This study aimed to investigate the possible role of miR-221 as a circulating biomarker in HCC patients undergoing sorafenib treatment as well as to evaluate its contribution to sorafenib resistance in advanced HCC. Experimental Design: A chemically induced HCC rat model and a xenograft mouse model, together with HCC-derived cell lines were employed to analyze miR-221 modulation by Sorafenib treatment. Data from the functional analysis were validated in tissue samples from surgically resected HCCs. The variation of circulating miR-221 levels in relation to Sorafenib treatment were assayed in the animal models and in two independent cohorts of patients with advanced HCC. Results: MiR-221 over-expression was associated with Sorafenib resistance in two HCC animal models and caspase-3 was identified as its target gene, driving miR-221 anti-apoptotic activity following Sorafenib administration. Lower pre-treatment miR-221 serum levels were found in patients subsequently experiencing response to Sorafenib and an increase of circulating miR-221 at the two months assessment was observed in responder patients. Conclusions: MiR-221 might represent a candidate biomarker of likelihood of response to Sorafenib in HCC patients to be tested in future studies. Caspase-3 modulation by miR-221 participates to Sorafenib resistance. Clin Cancer Res; 23(14); 3953–65. ©2017 AACR.
Relapse of Children with Aplastic Anemia after Immunosuppressive Therapy
Authors: Takuya Kamio, Etsuro Ito, Akira Ohara, Yoshiyuki Kosaka, Masahiro Tsuchida, Hideo Mugishima, Hiromasa Yabe, Akira Morimoto, Shouichi Ohga, Hiroshi Yagasaki, Fumio Bessho, Tatsutoshi Nakahata, Seiji Kojima
Journal: Blood (2008)
High Potential Cord Blood Mesenchymal Stem Cells with Angiogenic Properties for Endothelial Regeneration.
Authors: Tiziana Montemurro, Valentina Parazzi, Gabriella Spaltro, Elisa Montelatici, Gabriella Andriolo, Francesca Chelli, Mariele Viganò, Rosaria Giordano, Paolo Rebulla, Lorenza Lazzari
Journal: Blood (2010)
Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).
Authors: Thomas E Witzig, Julie M. Vose, Pier Luigi Zinzani, Craig B. Reeder, Rena Buckstein, Jonathan Polikoff, Pingshan Guo, Dennis Pietronigro, Annette Ervin-Haynes, Myron S Czuczman
Journal: Blood (2009)
The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine
Authors: Paraskevi Miltiades, Eleytheria Labrianidou, Theodoros P. Vassilakopoulos, Sotirios G Papageorgiou, Athanasios G. Galanopoulos, Sofia Vakalopoulou, Vassilia Garypidou, Evangelia Nakou, Emmanuil Spanoudakis, Maria Papaioannou, Helen A. Papadaki, Vasiliki Pappa, Konstantinos Tsatalas, Ioannis Kotsianidis
Journal: Blood (2012)
Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia
Authors: Edmond L Toy, Francis Vekeman, François Laliberté, Bree Dority, Daniel Perlman, Victoria Barghout, Mei Sheng Duh, Mark Lawrence Heaney
Journal: Blood (2008)
Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens
Authors: Guido Sauter, Till Clauditz, Stefan Steurer, Corinna Wittmer, Franziska Büscheck, Till Krech, Florian Lutz, Maximilian Lennartz, Luisa Harms, Lisa Lawrenz, Christina Möller-Koop, Ronald Simon, Frank Jacobsen, Waldemar Wilczak, Sarah Minner, Maria Christina Tsourlakis, Viktoria Chirico, Sören Weidemann, Alexander Haese, Thomas Steuber, Georg Salomon, Michael Matiu, Eik Vettorazzi, Uwe Michl, Lars Budäus, Derya Tilki, Imke Thederan, Dirk Pehrke, Burkhard Beyer, Christoph Fraune, Cosima Göbel, Marie Heinrich, Manuela Juhnke, Katharina Möller, Ahmed Abdulwahab Abdullah Bawahab, Ria Uhlig, Hartwig Huland, Hans Heinzer, Markus Graefen, Thorsten Schlomm
Journal: European Urology (2017)
Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.
Authors: Lloyd E. Damon, Jeff Johnson, Donna Niedzwiecki, Bruce D. Cheson, David Duane Hurd, Nancy L. Bartlett, John C. Byrd, Michael Kelly, Charles Linker, George P. Canellos
Journal: Blood (2006)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
Authors: H Ludwig, K Weisel, M T Petrucci, X Leleu, A M Cafro, L Garderet, C Leitgeb, R Foa, R Greil, I Yakoub-Agha, D Zboralski, S Vauléon, T Dümmler, D Beyer, A Kruschinski, K Riecke, M Baumann, M Engelhardt
Journal: Leukemia (2017)

Olaptesed pegol (olaptesed, NOX-A12) is a pegylated l-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine which signals through CXCR4 and CXCR7 regulating a variety of processes during multiple myeloma (MM) development.1 CXCL12 inhibition reduces the myeloma-supportive activity of the bone marrow microenvironment and mobilizes myeloma cells to the circulation.2 In addition, CXCL12α levels were reported to correlate with osteolytic bone lesions and with increased bone marrow angiogenesis.3 Targeting CXCL12, therefore, is a promising strategy for disrupting myeloma-stroma interactions and inhibiting myeloma growth and survival. Here, we report pharmacokinetic, pharmacodynamic, safety and efficacy data of olaptesed in patients with relapsed/refractory MM and present data on baseline CXCL12α levels in this patient cohort. This first-in-patient Phase IIa study aims to translate the novel concept of combining proteasome and CXCL12 inhibition into the clinic and builds on a preclinical proof-of-concept regarding the significance of CXCL12 blockade in MM2 and on Phase I data in healthy subjects.4 Combining CXCL12 inhibition with bortezomib and dexamethasone (VD) was investigated in 28 patients with relapsed/refractory MM, who were either bortezomib-naive or considered not refractory to bortezomib. The median number of prior lines of therapy was 2 (range: 1–5), 39 and 14% of the patients presented with 3 or 4 prior lines, respectively. Cytogenetics were tested in 21 patients and high risk features were found in 36% of them. 54% of patients had prior treatment with bortezomib, 39% had a prior stem cell transplant and 57% were refractory to prior treatment. Further details on patient characteristics (Supplementary Table S1) and inclusion and exclusion criteria are available in the Supplementary Information. In the pilot phase, three cohorts of three patients each (four patients in the 1 mg/kg cohort due to patient replacement) were administered single doses of 1, 2 or 4 mg/kg of olaptesed alone by slow intravenous bolus injection 2 weeks prior to starting the combination treatment. Combination treatment was administered for eight cycles of 21 days. An intra-patient escalation was applied for safety reasons as olaptesed was combined for the first time with VD in cancer patients. Olaptesed was given 1–2 h prior to bortezomib at doses of 1 mg/kg in cycle 1, 2 mg/kg in cycle 2 and 4 mg/kg in cycles 3–8. Bortezomib was given on days 1, 4, 8 and 11 of each 21-day treatment cycle as intravenous injection of 1.3 mg/m2. Oral dexamethasone (20 mg) was added on the day of and the day after bortezomib administration. An outline of the study and details of patients’ flow are given in Supplementary Figures S1 and S2.
Methylation-Independent Silencing of the Tumor Suppressor p15INK4B by CBFb-SMMHC in Acute Myeloid Leukemias with inv(16).
Authors: Jan Markus, Matthew T. Garin, Naomi Galili, Azra Raza, Michael J. Thirman, Michelle M. LeBeau, Janet D. Rowley, Linda Wolff
Journal: Blood (2005)
No asthma is found in third of adults with previous diagnosis
Authors: Jacqui Wise
Journal: BMJ (2017)

A third of adults who had had asthma diagnosed in the previous five years showed no evidence of current asthma, a study in JAMA has found.1

The study authors said that this could be due to spontaneous remission or initial misdiagnosis. They recommended that doctors review patients to see whether treatment can be stepped down or discontinued and that they order objective tests such as spirometry before and after bronchodilator administration to avoid unnecessary treatment or …
Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/d Is Tolerable and Highly Effective
Authors: Andreas Viardot, Mariele Goebeler, Jurgen S. Scheele, Gerhard Zugmaier, Richard Noppeney, Stefan Knop, Max S Topp, Dirk Nagorsen, Matthias Klinger, Margit Schmidt, Petra Klappers, Peter Kufer, Hermann Einsele, Ralf Bargou
Journal: Blood (2010)
Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation
Authors: Cagla Kayabasi, Cigir Biray Avci, Sunde Yilmaz Susluer, Tugce Balci, Yusuf Baran, Guray Saydam, Cumhur Gunduz
Journal: Blood (2012)
Fludarabine, Aracytine and Rituximab Based Chemotherapy In Patients with Refractory and Relapsed Mantle Cell Non-Hodgkin Lymphoma
Authors: Tommasina Perrone, Francesco Gaudio, Annamaria Giordano, Paola Curci, Alessandro Spina, Clara De' Risi, Giorgina Specchia
Journal: Blood (2010)
O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies
Authors: P Freund, M A Kerenyi, M Hager, T Wagner, B Wingelhofer, H T T Pham, M Elabd, X Han, P Valent, F Gouilleux, V Sexl, O H Krämer, B Groner, R Moriggl
Journal: Leukemia (2017)

The signal transducer and activator of transcription 5 (STAT5) regulates differentiation, survival, proliferation and transformation of hematopoietic cells. Upon cytokine stimulation, STAT5 tyrosine phosphorylation (pYSTAT5) is transient, while in diverse neoplastic cells persistent overexpression and enhanced pYSTAT5 are frequently found. Post-translational modifications might contribute to enhanced STAT5 activation in the context of transformation, but the strength and duration of pYSTAT5 are incompletely understood. We found that O-GlcNAcylation and tyrosine phosphorylation act together to trigger pYSTAT5 levels and oncogenic transcription in neoplastic cells. The expression of a mutated hyperactive gain-of-function (GOF) STAT5 without O-GlcNAcylation resulted in decreased tyrosine phosphorylation, oligomerization and transactivation potential and complete loss of oncogenic transformation capacity. The lack of O-GlcNAcylation diminished phospho-ERK and phospho-AKT levels. Our data show that O-GlcNAcylation of STAT5 is an important process that contributes to oncogenic transcription through enhanced STAT5 tyrosine phosphorylation and oligomerization driving myeloid transformation. O-GlcNAcylation of STAT5 could be required for nutrient sensing and metabolism of cancer cells.
Can NK Cells Play a Role in Anti-CD20 Immunotherapy for CLL Patients?.
Authors: Magali Le Garff-Tavernier, Christophe De Romeuf, Jean-Luc Teillaud, Julie Decocq, Charles-Antoine Dutertre, Patrice Debre, Helene Merle-Beral, Vincent Vieillard
Journal: Blood (2007)
An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim
Authors: Roberto Stasi, Adrian Newland, Bertrand Godeau, Victor Priego, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Catherine Jia, Angela Lopez
Journal: Blood (2013)
High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.
Authors: Jean-Luc Harousseau, Herve Avet-Loiseau, Michel Attal, Gerald Marit, Denis Caillot, Cyrille Hulin, Thierry Facon, Iain J. Webb, Claire Mathiot, Philippe Moreau
Journal: Blood (2009)